Metastatic Renal Cell Carcinoma ( mRCC)

11 clinical trials · Condition

Record	Firm	Date
International Multicentric Study ARON-1 (NCT05287464)	Hospital of Macerata	2022-03-10
A Retrospective Medical Record Review of First-Line Sunitinib Administration Schedules and Outcomes Among Patients With mRCC in Latin America (LA) (NCT04115189)	Pfizer	2019-12-13
Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments (NCT04175262)	Pfizer	2019-10-31
Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting (NCT02184416)	Pfizer	2014-10-31
Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib (NCT01514448)	Novartis Pharmaceuticals	2012-05-21
A Norwegian Observational Trial Evaluating the Treatment of Advanced Renal Cell Cancer Patients Under Treatment of Afinitor (NCT01390519)	Novartis Pharmaceuticals	2011-06-01

Every clearance here is in the API, with alerts when new ones post.